CRO Inotiv has completed the sale of its business in Israel, which it described as part of the site optimisation plan for its Research Models & Services segment that it launched last year. The buyer was not named. Further assets remain for sale, which have been closed as part of the process.

Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.